Member Info for bobbust

At 9.3 is that a delayed buy?

All but one on 10p the other 10.1.
Not seen that before

Seriously who is it.
If you are on here please let me know why.

RNS.
Yes I would say.
But timing is the key.
One has started the other in a couple of weeks.
They have known this for a few weeks at least and the TCR comment!!

"Samantha will be invaluable in immunological design of the upcoming trials and spearheading the new TCR therapeutics and I am very excited to add such an experienced scientist to the team."

RNS tomorrow

onwards and upwards.

Team strengthened ready to move forward

SCLP.GB.PL is now on LSE is this just the trades on NEX?
and is this new?
I have not seen it before

Emailed Sally and Cliff replied.
Trail still on track to start H1 2019. will update the market if anything changes

Not sure we would need £20 to develop Modi 3.
Given how much we have spent in total to get Scib 1 & 2 plus Modi 1 and 2 this far.
And some of last years winners and this year's entries would not need £20m.
If you spent 50% on overheads that's 20 scientists at £100 k a year for 5 years.

I brought this up a week ago.
at the AGM Sally said it was unlikely that the UK trial would start without US approval.
I wonder if this may now change as its an administrative problem on the US side.

Not to Sally.
It may provide the external validation which could have a huge effect on the sp

Being disingenuous..?
If we win GC and it gets to become a product and its based on Modi 3 we will receive royalties.
And will be paid to work with companies with deep pockets.
If it was not a benefit to scancell they would not have entered

Being disingenuous..?
If we win GC and it gets to become a product and its based on Modi 3 we will receive royalties.
And will be paid to work with companies with deep pockets.
If it was not a benefit to scancell they would not have entered

Strange!,!
News guaranteed next week.
More chance of rising this week on anticipation of the news

Look at the science not the SP.
The SP will follow.
If it was easy anyone could do it.
Short term SP performance is not the issue.
Long term this will not be a dog.
Lot more good news than GC to come

why not. if it goes to 30p I will be rich

yes an extra £5k in now wont make any difference if its £6

but where else can you get a multi bagger with proven science?

At the 2017 AGM the board seamed very confident that the SP would be positively effected by upcoming external validation.
Since then we have had Scib2/CRUK deal, CRUK GC, BioTNech collaboration.
Lets hope that if we win the GC we get the upturn they excpected.
down a penny if we loose
Up 10-15 if we win

They could give it other teams who are doing good work but has less of a commercial prospect.
That said why include us in the last 10 if they are not going to give it to someone with potential commercial prospects

I think the board has done wonders to get us to this point.
It's still our own IP. Low dilution.
If they had done a deal previously it would be for a lot less cash than they will get latter this year.
50% down so you have a chunk of shares at 16p. A £400 m deal and you will be 600% up

sorry mixing my Genentech and BioNtec.
Is Genentech doing something similar here to what BioNTec is doing?